PharmaBiome has developed a drug development platform for targeted microbiome therapeutics, combining dynamic microbiome analysis and co-cultivation-based assembly technology. By actively engineering composition and activity of our multi-strain consortia we solve current translational shortcomings.
Products, services, technology
The platform has extensively been validated preclinically and will be advanced into humans based on two strategically selected indications: The first and most progressed is acute Graft vs. Host Disease (aGvHD), followed by Ulcerative Colitis (UC). Both first in human studies are planned for 2024/25.
As microbiome experts, we are looking to leverage the potential of our platform through industrial partnerships to bring microbiome therapeutics into clinics. We are active in the fields of oncology as well as inflammatory bowel diseases and can address indications of interest for a partner.
The microbiome is the missing piece in many therapeutic regimens in a multitude of immune-related diseases. We unlock the therapeutic potential of the microbiome with our broadly applicable platform technology, bringing solutions to millions of patients worldwide.
Ahead of the field at the time, PharmaBiome had the perseverance to develop the world's first true drug-development platform for microbiome therapeutics. We have anticipated the now evident shortcomings of the first translational approaches and will give this novel modality the chance it deserves.
Rebiotix (a Ferring company) for bringing the first microbiome product to FDA approval. Seventure for being the first to pioneer the development of defined bacterial mixes. Vedanta for paving the way for regulatory and mechanistic understanding of bacterial mixes to treat specific targets.
What are the core strengths of your current team and what skills are you looking forward to integrate in the future?
PharmaBiome’s unique heritage in intestinal microbiology, gut biotechnology, data science and gastroenterology makes it a strong preclinical company. We are now looking forward to further develop our team with translational and clinical expertise for the clinical validation of our platform.
Darm mit Charme
The microbiome needs to be present in all clinical considerations. A strong biotech nation like Switzerland should have a pioneering role in this new modality.
Pharmaceutical companies that are looking to enhance the potential of their pipeline with true microbiome drugs.